渭河阶地全新世土壤粒度成分高分辨率研究

通过对渭河阶地全新世土壤的野外考察和粒度成分的高分辨率分析研究，揭示了该区域褐色土的成壤作用过程与季风气候变化的关系。研究表明渭河第二级阶地褐色土形成在全新世气候最适宜期（8500－3100a B.P.），从8500a B.P.开始该土壤开始发育，老官台文化兴起。从3100a B.P.开始的气候干旱化和沙尘暴堆积形成了黄土L。层。西周时期对应于该干旱期的初期。     

红肉脐橙果肉中主要色素的定性及色素含量的变化

 运用薄层层析法及二极管阵列检测器与高效液相色谱联用的方法, 确定红肉脐橙果肉中含有番茄红素和β- 胡萝卜素两种主要色素, 它们在液相色谱图中占总峰面积(计溶剂峰) 的73. 57 %～77. 78 % , 番茄红素占55. 36 %～58. 49 % , β- 胡萝卜素占18. 21 %～19. 93 %。利用反相高效液相色谱仪以及番茄红素和β- 胡萝卜素标样制作标准曲线, 测定果实发育及室温贮存过程中色素的变化动态, 结果表明, 该脐橙果肉中的番茄红素在成熟期含量最高, 达109. 67μg·g^-1DM, β- 胡萝卜素此时也达到最高值(15. 52μg·g^-1DM) ; 番茄红素的含量在采收后基本呈下降趋势(但采后30 d 有显著升高) , 说明果肉中存在类胡萝卜素采后合成的现象; 贮存4 个月后, 番茄红素含量急剧降低至最高时的1/ 10。     

Changes of myocardial glycogen content and right ventricular function in hypoxia swimming rats

AIM: To investigate the changes of myocardium glycogen content and the relation ship between changes of the myocardial glycogen content and the myocardial function. METHODS: Male Wistar rats were placed in (hypoxia rats) and made to swim in (hypoxia swimming rats) a hypobaxic chamber simulating an altitude of 5 000 m above sea level. The content of myocardium glycogens was determined by colorimetry. RESULTS: The myocardium
glycogen content of rats significantly reduced along with the prolongation of hypoxic exposure and approached to control level in hypoxia swimming rats. The myocardial function of right ventricule was improved significantly compared with control group.CONCLUSION: Moderate exercise (swimming) is beneficial to hypoxic adaptation of rats under the condition of chronic hypoxia.     

利用紫茎泽兰栽培田头菇的研究

利用紫茎泽兰作为原料栽培田头菇 ,同时利用稻草和棉籽壳为原料栽培田头菇作对照。研究结果表明 ,代料熟料栽培田头菇的培养基配方中 ,以紫茎泽兰为主要原料的配方A效果最好 ,生物学效率比对照的稻草培养基平均增产 80 %以上。利用紫茎泽兰鲜草和干草作培养基的单产量差异不明显。     

9种除草剂对花生白绢病菌的影响

在实验室条件下测定了氟乐灵、乙草胺、异丙甲草胺、异恶草酮、乳氟禾草灵、乙氧氟草醚、三氟羧草醚、恶草酮、二甲戊乐灵等9种除草剂对花生白绢病菌Sclerotium rolfsi Sacc.的影响.结果表明:9种除草剂对花生白绢病病菌的毒力有较大差异,三氟羧草醚和乙氧氟草醚的毒力较高,IC50分别为7.88mg·L-1和18.91mg·L-1;9种除草剂对菌丝干重均有抑制作用,且随剂量的升高而升高,乙氧氟草醚和三氟羧草醚抑制作用最明显,在100mg·L-1和50mg·L-1时抑制率均达90%以上;除乙草胺和异丙甲草胺部分剂量外,其他除草剂对菌核数量均有不同程度的抑制作用,三氟羧草醚作用最为明显,在供试剂量下抑制率均达96%以上;除乙草胺、氟乐灵在供试剂量下对菌核单重有抑制作用外,其他除草剂在多数剂量下对菌核单重均有刺激作用,三氟羧草醚在50mg·L-1时,是对照菌核单重的8.34倍;而各种除草剂在供试剂量下,对菌核萌发均没有影响.     

人参提取液体外抑制IHNV作用效果研究

探究人参提取液体外抑制CCB细胞感染IHNV的能力,构建体外CCB细胞模型,运用RTCA技术和MTT法测得不同浓度人参提取液对IHNV抑制作用曲线,并从阻断病毒复制和杀灭病毒两方面讨论人参提取液作用效果。结果表明,4%人参提取液对IHNV具有明显抑制作用,能够在16 h内保护细胞不受IHNV病毒的侵染,其中2 h时对病毒灭活抑制率最高达到51.5%,1~12 h内对病毒复制有持续抑制作用。研究可为IHVN防治药物的研发提供新的思路及参考。     

UHPLC-Q/TOF MS结合HPLC-DAD定性和定量分析硫酸黏菌素可溶性粉中的未知添加物

定性和定量分析一批兽药硫酸黏菌素可溶性粉中的未知添加物。照《中国兽药典》2010年版一部对该批检品用微生物检定法进行含量测定时,发现该样品的抑菌圈为虚圈,用薄层色谱鉴别该样品,未显示与标准品溶液一致的主斑点,怀疑该样品中有处方外非法添加物。采用超高效液相色谱-四级杆-飞行时间质谱(UHPLC-Q/TOF MS)对该样品进行筛查,发现疑似添加物,并使用液相色谱-二极管阵列检测(HPLC-DAD)法进行了双重确证和含量测定。该样品中非法添加物确证为磺胺氯达嗪和甲氧苄啶,添加量分别为58.5 mg/g和13.4 mg/g。本研究通过建立筛查方法为监管部门提供技术支撑,通过分析非法添加物的可能原因为打击兽药处方外非法添加提供了思路。     

复方茵陈保肝口服液的制备与提取工艺研究

确定复方茵陈保肝口服液的制备工艺并建立质量标准。采用紫外分光光度法,以滨蒿内酯为对照品,在340 nm处测定按照不同工艺制备的口服液中香豆素含量,以香豆素含量高低作为优化标准。利用薄层色谱法对口服液中茵陈、党参、淫羊藿进行定性鉴别。用高效液相色谱法对口服液成品香豆素含量进行测定。口服液在料液比为1∶20,醇沉体积分数50%,煎煮时间2 h条件时香豆素含量最高。薄层色谱中斑点清晰,阴性对照无干扰。高效液相色谱法中滨蒿内酯在6.8~136μg范围内具有良好的线性关系,平均加样回收率为98.79%,RSD为1.39%。试验优化的制备工艺方法简单可行,建立的质量标准适用于复方茵陈保肝口服液的质量控制。     

Pharmacokinetics of articaine hydrochloride and its metabolite articainic acid after subcutaneous administration in red deer (Cervus elaphus)

AIM: To develop and validate a simple and sensitive method using liquid chromatography-mass spectrometry (LC-MS) for quantification of articaine, and its major metabolite articainic acid, in plasma of red deer (Cervus elaphus), and to investigate the pharmacokinetics of articaine hydrochloride and articainic acid in red deer following S/C administration of articaine hydrochloride as a complete ring block around the antler pedicle.

METHODS: The LC-MS method was validated by determining linearity, sensitivity, recovery, carry-over and repeatability. Articaine hydrochloride (40?mg/mL) was administered S/C to six healthy male red deer, at a dose of 1?mL/cm of pedicle circumference, as a complete ring block around the base of each antler. Blood samples were collected at various times over the following 12 hours. Concentrations in plasma of articaine and articainic acid were quantified using the validated LC-MS method. Pharmacokinetic parameters of articaine and articainic acid were estimated using non-compartmental analysis.

RESULTS: Calibration curves were linear for both articaine and articainic acid. The limits of quantifications for articaine and articainic acid were 5 and 10?ng/mL, respectively. Extraction recoveries were >72% for articaine and >68% for articainic acid. After S/C administration as a ring block around the base of each antler, mean maximum concentrations in plasma (C_max) of articaine were 1,013.9 (SD 510.1) ng/mL, detected at 0.17 (SD 0.00) hours, and the C_max for articainic acid was 762.6 (SD 95.4) ng/mL at 0.50 (SD 0.00) hours. The elimination half-lives of articaine hydrochloride and articainic acid were 1.12 (SD 0.17) and 0.90 (SD 0.07) hours, respectively.

CONCLUSIONS AND CLINICAL RELEVANCE: The LC-MS method used for the quantification of articaine and its metabolite articainic acid in the plasma of red deer was simple, accurate and sensitive. Articaine hydrochloride was rapidly absorbed, hydrolysed to its inactive metabolite articainic acid, and eliminated following S/C administration as a ring block in red deer. These favourable pharmacokinetic properties suggest that articaine hydrochloride should be tested for efficacy as a local anaesthetic in red deer for removal of velvet antlers. Further studies to evaluate the safety and residues of articaine hydrochloride and articainic acid are required before articaine can be recommended for use as a local anaesthetic for this purpose.     

Pharmacokinetics of multiple doses of transdermal flunixin meglumine in adult Holstein dairy cows

A transdermal formulation of the nonsteroidal anti‐inflammatory drug, flunixin meglumine, has been approved in the United States and Canada for single‐dose administration. Transdermal flunixin meglumine was administered to 10 adult Holstein cows in their second or third lactation at the label dose of 3.33 mg/kg every 24 hr for three total treatments. Plasma flunixin concentrations were determined using high‐pressure liquid chromatography with mass spectroscopy (HPLC ‐MS ). Pharmacokinetic analysis was completed on each individual animal with noncompartmental methods using computer software. The time to maximum drug concentration (T max) was 2.81 hr, and the maximum drug concentration was 1.08 μg/ml. The mean terminal half‐life (T½) was determined to be 5.20 hr. Clearance per fraction absorbed (Cl/F) was calculated to be 0.294 L/hr kg^?1, and volume of distribution of fraction (V z/F ) absorbed was 2.20 L/kg. The mean accumulation factor was 1.10 after three doses. This indicates changes in dosing may not be required when giving multiple doses of flunixin transdermal. Further work is required to investigate the clinical efficacy of transdermal flunixin after multiple daily doses.